Kategorija: Moksliniai tyrimai

"uniQure" paskelbė, kad atnaujina pacientų registraciją didesnės dozės tyrime AMT-130

A Message to the Huntington’s Disease Community from uniQure Dear Huntington’s Disease Community Members, This morning, uniQure issued a press release which included an update on our clinical trial ofAMT-130 […]

"Wave Life Sciences" skelbia teigiamus 1b/2a fazės SELECT-HD tyrimo rezultatus, kurie rodo, kad WVE-003 su Huntingtono liga yra selektyvus alelio taikinys

September 20, 2022 at 7:30 AM EDT PDF Version Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30 […]

"uniQure" praneša apie atnaujintus duomenis apie mažų dozių kohortą I/II fazės klinikiniame AMT-130 genų terapijos, skirtos Huntingtono ligai gydyti, tyrime

~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT […]

"Annexon Biosciences" atnaujina tyrimų rezultatus

ANNEXON BIOSCIENCES REPORTS PHASE 2 CLINICAL TRIAL RESULTS DEMONSTRATING UPSTREAM CLASSICAL COMPLEMENT INHIBITION ASSOCIATED WITH CLINICAL BENEFIT IN HUNTINGTON’S DISEASE On June 7, Annexon, that is a clinical-stage biopharmaceutical company […]

Internetinis seminaras - viskas, ką reikia žinoti apie "Proof-HD

Yesterday, Prilenia hosted a webinar updating on the Phase III trial with Pridopidine. Thank you to everyone who join and a special thanks to our speakers, Michael Hayden, Andrew Feigin, […]

Naujausios žinios - "Roche" planuoja naują tominerseno tyrimą

Some encouraging news has just come in from Roche.  Analysis of the results of Roche’s Phase III GENERATION HD1 trial, which was stopped in March 2021, has found that a […]